Literature DB >> 35953765

Liquid antisolvent crystallization of pharmaceutical compounds: current status and future perspectives.

Rahul Kumar1, Amit K Thakur2, Nilanjana Banerjee2, Ashutosh Kumar3, Gajendra Kumar Gaurav4, Raj Kumar Arya5.   

Abstract

The present work reviews the liquid antisolvent crystallization (LASC) to prepare the nanoparticle of pharmaceutical compounds to enhance their solubility, dissolution rate, and bioavailability. The application of ultrasound and additives is discussed to prepare the particles with narrow size distribution. The use of ionic liquid as an alternative to conventional organic solvent is presented. Herbal compounds, also known for low aqueous solubility and limited clinical application, have been crystalized by LASC and discussed here. The particle characteristics such as particle size and particle size distribution are interpreted in terms of supersaturation, nucleation, and growth phenomena. To overcome the disadvantage of batch crystallization, the scientific literature on continuous flow reactors is also reviewed. LASC in a microfluidic device is emerging as a promising technique. The different design of the microfluidic device and their application in LASC are discussed. The combination of the LASC technique with traditional techniques such as high-pressure homogenization and spray drying is presented. A comparison of product characteristics prepared by LASC and the supercritical CO2 antisolvent method is discussed to show that LASC is an attractive and inexpensive alternative for nanoparticle preparation. One of the major strengths of this paper is a discussion on less-explored applications of LASC in pharmaceutical research to attract the attention of future researchers.
© 2022. Controlled Release Society.

Entities:  

Keywords:  Antisolvent; Bioavailability; Crystallization; Microfluidic; Nanoparticle

Year:  2022        PMID: 35953765     DOI: 10.1007/s13346-022-01219-1

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   5.671


  59 in total

1.  Design and Development of Repaglinide Microemulsion Gel for Transdermal Delivery.

Authors:  Ujwala A Shinde; Sheela H Modani; Kavita H Singh
Journal:  AAPS PharmSciTech       Date:  2017-07-17       Impact factor: 3.246

2.  Preparation and characterization of a synthetic curcumin analog inclusion complex and preliminary evaluation of in vitro antileishmanial activity.

Authors:  Luciana Matos Alves Pinto; Oluwatomide Adeoye; Sérgio Scherrer Thomasi; Ana Paula Francisco; Manuela Colla Carvalheiro; Helena Cabral-Marques
Journal:  Int J Pharm       Date:  2020-08-25       Impact factor: 5.875

3.  Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study.

Authors:  Nirmal Shah; Avinashkumar Seth; R Balaraman; Girish Sailor; Ankur Javia; Dipti Gohil
Journal:  Drug Dev Ind Pharm       Date:  2017-12-04       Impact factor: 3.225

4.  In situ artificial membrane permeation assay under hydrodynamic control: correlation between drug in vitro permeability and fraction absorbed in humans.

Authors:  Matěj Velický; Kin Y Tam; Robert A W Dryfe
Journal:  Eur J Pharm Sci       Date:  2011-08-16       Impact factor: 4.384

5.  Enhanced dissolution/caco-2 permeability, pharmacokinetic and pharmacodynamic performance of re-dispersible eprosartan mesylate nanopowder.

Authors:  Prachi Shekhawat; Milind Bagul; Diptee Edwankar; Varsha Pokharkar
Journal:  Eur J Pharm Sci       Date:  2019-02-22       Impact factor: 4.384

6.  Oral bioavailability improvement of felodipine using tailored microemulsion: Surface science, ex vivo and in vivo studies.

Authors:  Akshay R Koli; Ketan M Ranch; Hetal P Patel; Rajesh K Parikh; Dinesh O Shah; Furqan A Maulvi
Journal:  Int J Pharm       Date:  2021-01-23       Impact factor: 5.875

7.  Impact of co-administered stabilizers on the biopharmaceutical performance of regorafenib amorphous solid dispersions.

Authors:  Martin Müller; Raphael Wiedey; Werner Hoheisel; Peter Serno; Jörg Breitkreutz
Journal:  Eur J Pharm Biopharm       Date:  2021-10-28       Impact factor: 5.571

8.  Predicting in vivo performance of fenofibrate amorphous solid dispersions using in vitro non-sink dissolution and dissolution permeation setup.

Authors:  Karoline Aagaard Lentz; Jakob Plum; Bente Steffansen; Per-Ola Arvidsson; Diana Højmark Omkvist; Anders Just Pedersen; Carl Johan Sennbro; Gitte Pommergaard Pedersen; Jette Jacobsen
Journal:  Int J Pharm       Date:  2021-10-13       Impact factor: 5.875

9.  Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion.

Authors:  Sichen Song; Chenguang Wang; Shan Wang; Ronald A Siegel; Changquan Calvin Sun
Journal:  Int J Pharm       Date:  2021-10-21       Impact factor: 5.875

10.  Investigation of Praziquantel/Cyclodextrin Inclusion Complexation by NMR and LC-HRMS/MS: Mechanism, Solubility, Chemical Stability, and Degradation Products.

Authors:  Tatjana Kezele Špehar; Marijana Pocrnić; David Klarić; Branimir Bertoša; Ana Čikoš; Mario Jug; Jasna Padovan; Snježana Dragojević; Nives Galić
Journal:  Mol Pharm       Date:  2021-10-21       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.